This study evaluates the safety and diagnostic performance characteristics of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B).
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Prostate CancerDiagnosticImaging2301PET/CTPyLPSMAradical prostatectomymetastatic prostate cancerrecurrent prostate cancer
You can join if…
Open to males ages 18 years and up
Histologically confirmed adenocarcinoma of the prostate.
Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
Cohort A Only:
At least high risk prostate cancer defined by NCCN Guidelines Version 3.2016(clinical stage ≥T3a or PSA>20 ng/mL or Gleason score ≥8).
Scheduled or planned radical prostatectomy with PLND.
Cohort B Only:
Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan(99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.
If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed.
Scheduled or planned percutaneous biopsy of at least one amenable lesion.
You CAN'T join if...
Subjects administered any radioisotope within five physical half-lives or any IV X-ray contrast medium within 24 hours or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug injection.
Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Cohort A Only:
Patients with prior androgen deprivation therapy or any investigational neoadjuvant agent or intervention
Cohort B Only:
Prior radiation or ablative therapy to intended site of biopsy
Initiation of new therapy for recurrent and/or progressive metastatic disease since radiographic documentation of recurrence/progression.
University of California at San Francisco (UCSF) - Mt. Zion Hospitalaccepting new patients San Francisco, California, 94143, United States
Washington University Mallinckrodt Institute of Radilogyaccepting new patients Saint Louis, Missouri, 63110, United States
University of Chicagoaccepting new patients Chicago, Illinois, 60637, United States
University of Michigan Cancer Centeraccepting new patients Ann Arbor, Michigan, 48109, United States
Johns Hopkins Universityaccepting new patients Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Cancer Centeraccepting new patients New York, New York, 10065, United States
Yale University Department of Radiology and Biomedical Imagingaccepting new patients New Haven, Connecticut, 06520, United States
Jewish General Hospitalaccepting new patients Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Quebec (CHUQ)accepting new patients Quebec, Canada
Dana Farber Cancer Instituteaccepting new patients Boston, Massachusetts, 02115, United States